SHOULDER INNOVATIONS, INC. Research and Development Expense
SHOULDER INNOVATIONS, INC. (SI) reported Research and Development Expense of $3.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- SHOULDER INNOVATIONS, INC. research and development expense for the quarter ending 2026-06-30 was $3.39M, a 141.18% increase year-over-year.
- SHOULDER INNOVATIONS, INC. research and development expense for the quarter ending 2026-03-31 was $3.75M, a 137.14% increase year-over-year.
- SHOULDER INNOVATIONS, INC. research and development expense for the quarter ending 2025-12-31 was $3.22M, a 175.66% increase year-over-year.
- SHOULDER INNOVATIONS, INC. research and development expense for the quarter ending 2025-09-30 was $1.52M, a 39.91% increase year-over-year.
- SHOULDER INNOVATIONS, INC. research and development expense for fiscal 2025 was $7.73M, a 72.22% increase from fiscal 2024.
- SHOULDER INNOVATIONS, INC. research and development expense for fiscal 2024 was $4.49M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.39M 10-Q · filed 2026-08-06 | $7.14M 10-Q · filed 2026-08-06 | $10.36M derived: sum of 3 quarters · filed 2026-08-06 | $11.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.75M 10-Q · filed 2026-05-13 | $6.97M derived: sum of 2 quarters · filed 2026-05-13 | $8.50M derived: sum of 3 quarters · filed 2026-05-13 | $9.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.74M derived: sum of 2 quarters · filed 2026-03-10 | $6.15M derived: sum of 3 quarters · filed 2026-08-06 | $7.73M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.52M 10-Q · filed 2025-11-12 | $2.93M derived: sum of 2 quarters · filed 2026-08-06 | $4.51M 10-Q · filed 2025-11-12 | $5.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.41M 10-Q · filed 2026-08-06 | $2.99M 10-Q · filed 2026-08-06 | $4.16M derived: sum of 3 quarters · filed 2026-08-06 | $5.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.58M 10-Q · filed 2026-05-13 | $2.75M derived: sum of 2 quarters · filed 2026-05-13 | $3.84M derived: sum of 3 quarters · filed 2026-05-13 | $5.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.26M derived: sum of 2 quarters · filed 2026-03-10 | $3.42M derived: sum of 3 quarters · filed 2026-03-10 | $4.49M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.09M 10-Q · filed 2025-11-12 | $2.25M derived: sum of 2 quarters · filed 2025-11-12 | $3.32M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.16M 10-Q · filed 2025-09-09 | $2.23M 10-Q · filed 2025-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |